alpha-aminopyridine has been researched along with Rhabdomyosarcoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunac, AC; Castex, MP; Gomez-Brouchet, A; Guillemot, D; Karanian, M; Laprie, A; Laurent, C; Le Guellec, S; Le Loarer, F; Pierron, G | 1 |
| Coarfa, C; Dasgupta, A; Kurenbekova, L; Landesman, Y; Patel, T; Rainusso, N; Rajapakse, K; Shuck, RL; Sierra, L; Tsang, SV; Unger, T; Yustein, JT | 1 |
| Bennett, CE; Cam, H; Coss, CC; Gardner, HL; Guttridge, DC; Hariharan, S; Houghton, P; LeBlanc, AK; Lin, J; Ling, Y; London, CA; Mo, X; Phelps, MA; Ren, L; Roberts, R; Xiao, H; Yu, PY | 1 |
| Cao, L; Davis, S; Helman, LJ; Kang, Z; Meltzer, PS; Walker, R; Yu, Y; Zhu, YJ | 1 |
| Avnet, S; Baldini, N; Di Pompo, G; Lattanzi, G; Mai, A; Rotili, D; Salerno, M; Valente, S; Zwergel, C | 1 |
5 other study(ies) available for alpha-aminopyridine and Rhabdomyosarcoma
| Article | Year |
|---|---|
The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript.
Topics: Adolescent; Aminopyridines; Anaplastic Lymphoma Kinase; Bone Neoplasms; Carbazoles; Chemoradiotherapy; DNA-Binding Proteins; Female; Humans; Lactams; Lactams, Macrocyclic; Oncogene Proteins, Fusion; Piperidines; Pyrazoles; Rhabdomyosarcoma; RNA-Binding Protein FUS; Transcription Factors | 2020 |
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma.
Topics: Acrylamides; Aminopyridines; Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Child; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; p21-Activated Kinases; Pyrazoles; Pyrroles; ras Proteins; Rhabdomyosarcoma; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Topics: Aminopyridines; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokines; Dogs; Female; Humans; Lung Neoplasms; Mice; Osteosarcoma; Phosphorylation; Rhabdomyosarcoma; Sarcoma, Ewing; STAT3 Transcription Factor; Sulfonamides; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.
Topics: Aminopyridines; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 2; Mice; Mice, SCID; Molecular Targeted Therapy; Morpholines; Pyrimidines; Receptor, IGF Type 1; Rhabdomyosarcoma; Treatment Failure; Xenograft Model Antitumor Assays | 2014 |
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Topics: Aminopyridines; Apoptosis; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Osteogenesis; Osteosarcoma; Pyrimidinones; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Structure-Activity Relationship | 2015 |